Effect of Nephritis Rehabilitation Tablets combined with tacrolimus in treatment of idiopathic membranous nephropathy

Table 1 Comparison of therapeutic effects between the two groups, n (%)

Group	Number	Complete remission	Partial remission	Invalid	Total efficiency
Study	42	26 (61.90)	12 (28.57)	4 (9.52)	38 (90.48)
Control	42	16 (38.10)	14 (33.33)	12 (28.57)	30 (71.43)
χ2					4.941
P value					0.026

Table 2 Comparison of renal function indexes between the two groups (mean ± SD)

Time	Group	Number	Scr (umol/L)	Serum albumin (g/L)	24 h urinary protein quantification (g)
Before treatment	Study	42	121.97 ± 40.36	24.21 ± 2.35	7.41 ± 2.19
	Control	42	124.55 ± 38.68	23.64 ± 2.51	7.69 ± 2.32
	t		0.299	1.074	0.569
	P value		0.766	0.286	0.571
After 12 weeks of treatment	Study	42	86.23 ± 21.61a	36.69 ± 3.71a	1.63 ± 0.59a
	Control	42	101.55 ± 23.67a	31.26 ± 3.35a	2.89 ± 0.79a
	t		3.098	7.040	8.282
	P value		0.003	0.000	0.000

^aP < 0.05, before treatment vs after 12 wk of treatment.

Table 3 Comparison of urinary IgG4 and C5b-9 levels between the two groups (mean ± SD)

Time	Group	Number	IgG4 (ug/mmol)	C5b-9 (ng/mg)
Before treatment	Study	42	14.67 ± 2.39	83.79 ± 10.66
	Control	42	15.19 ± 2.53	85.65 ± 11.20
	t		0.968	0.780
	P value		0.336	0.438
After 12 weeks of treatment	Study	42	1.45 ± 0.29a	44.81 ± 9.39a
	Control	42	3.13 ± 0.71a	55.37 ± 10.23a
	t		14.196	4.928
	P value		0.000	0.000

^aP < 0.05, before treatment vs after 12 wk of treatment.

Table 4 Comparison of incidence of adverse reactions between the two groups, n (%)

Group	Number	Elevated transaminase	Gastrointestinal reaction	Vomiting and nausea	Dizzy	Total incidence rate
Study	42	1 (2.38)	1 (2.38)	2 (4.76)	1 (2.38)	5 (11.90)
Control	42	1 (2.38)	1 (2.38)	0 (0.00)	1 (2.38)	3 (7.14)
χ2						0.138
P value						0.710